Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.
Lefèvre
Gilbert
G
Novartis Pharma AG, Exploratory Development, WSJ-210.4.25, CH-4002 Basel, Switzerland. gilbert.lefevre@novartis.com
Pommier
Françoise
F
Sedek
Greg
G
Allison
Mark
M
Huang
Hsun-Lun Aaron
HL
Kiese
Beate
B
Ho
Yu-Yun
YY
Appel-Dingemanse
Silke
S
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000368:Aged / Q000502:physiology*; D019540:Area Under Curve; D001596:Benzylamines / Q000097:blood / Q000378:metabolism; D001682:Biological Availability; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D018592:Cross-Over Studies; D004244:Dizziness / Q000139:chemically induced; D005260:Female; D006207:Half-Life; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010627:Phenethylamines; D010636:Phenols / Q000097:blood / Q000378:metabolism; D048448:Phenylcarbamates / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics*; D000068836:Rivastigmine; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D012996:Solutions; D053719:Tandem Mass Spectrometry; D014839:Vomiting / Q000139:chemically induced
C494046:3-(1-dimethylaminoethyl)phenol; D001596:Benzylamines; D002800:Cholinesterase Inhibitors; D010627:Phenethylamines; D010636:Phenols; D048448:Phenylcarbamates; D012996:Solutions; D000068836:Rivastigmine